12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

VB-201: Phase II started

VBL began a double-blind, placebo-controlled, dose-ranging Phase II trial to evaluate oral VB-201 daily for 4 weeks in 320 patients with elevated high...

Read the full 91 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >